The androgen receptor (AR) is the dominant growth factor in prostate cancer (PCa).Therefore, understanding how ARs regulate the human transcriptome is of paramountimportance. The early effects of castration on human PCa have not previously beenstudied 27 patients medically castrated with degarelix 7 d before radical prostatec-tomy. We used mass spectrometry, immunohistochemistry, and gene expression array(validated by reverse transcription-polymerase chain reaction) to compare resectedtumour with matched, controlled, untreated PCa tissue. All patients had levels ofserum androgen, with reduced levels of intraprostatic androgen at prostatectomy.We observed differential expression of known androgen-regulated genes (TMPRSS2,KLK3, CAMKK2, FKBP5)...
Purpose: Progression to the castration-resistant state is the incurable and lethal end stage of pros...
Purpose: To evaluate changes in the expression of androgen receptor (AR) and its variants (ARVs) in ...
Androgen receptor (AR) signaling remains the key therapeutic target in the management of hormone-nai...
The androgen receptor (AR) is the dominant growth factor in prostate cancer (PCa).Therefore, underst...
AbstractThe androgen receptor (AR) is the dominant growth factor in prostate cancer (PCa). Therefore...
The androgen receptor (AR) is the dominant growth factor in prostate cancer (PCa). Therefore, unders...
Appraising the crucial role of androgen receptor (AR) in prostate cancer (PCa) initiation and progre...
SummaryThe androgen receptor (AR) regulates prostate cell growth in man, and prostate cancer is the ...
BACKGROUND: Despite the importance of androgen receptor (AR) signalling to prostate cancer developme...
Prostate cancer is one of the most common cancers diagnosed and the second leading cause of cancer r...
Background Expression of the androgen receptor (AR) is associated with androgen-dependent proliferat...
The androgen receptor (AR) is a prostate master transcription factor. It binds to genetic enhancers,...
The androgen receptor (AR) signalling axis plays a vital role in the development, function and homeo...
In the majority of castration-resistant prostate cancer (CRPC), prostate-specific antigen (PSA), pro...
Since the growth of prostate cancer is androgen-sensitive, metastatic disease has been treated by ho...
Purpose: Progression to the castration-resistant state is the incurable and lethal end stage of pros...
Purpose: To evaluate changes in the expression of androgen receptor (AR) and its variants (ARVs) in ...
Androgen receptor (AR) signaling remains the key therapeutic target in the management of hormone-nai...
The androgen receptor (AR) is the dominant growth factor in prostate cancer (PCa).Therefore, underst...
AbstractThe androgen receptor (AR) is the dominant growth factor in prostate cancer (PCa). Therefore...
The androgen receptor (AR) is the dominant growth factor in prostate cancer (PCa). Therefore, unders...
Appraising the crucial role of androgen receptor (AR) in prostate cancer (PCa) initiation and progre...
SummaryThe androgen receptor (AR) regulates prostate cell growth in man, and prostate cancer is the ...
BACKGROUND: Despite the importance of androgen receptor (AR) signalling to prostate cancer developme...
Prostate cancer is one of the most common cancers diagnosed and the second leading cause of cancer r...
Background Expression of the androgen receptor (AR) is associated with androgen-dependent proliferat...
The androgen receptor (AR) is a prostate master transcription factor. It binds to genetic enhancers,...
The androgen receptor (AR) signalling axis plays a vital role in the development, function and homeo...
In the majority of castration-resistant prostate cancer (CRPC), prostate-specific antigen (PSA), pro...
Since the growth of prostate cancer is androgen-sensitive, metastatic disease has been treated by ho...
Purpose: Progression to the castration-resistant state is the incurable and lethal end stage of pros...
Purpose: To evaluate changes in the expression of androgen receptor (AR) and its variants (ARVs) in ...
Androgen receptor (AR) signaling remains the key therapeutic target in the management of hormone-nai...